PRTH-101 is an antibody that targets DDR1, a protein involved in tumour growth. Credit: Nemes Laszlo/Shutterstock.

Incendia Therapeutics has enrolled the first subject in a Phase Ic clinical trial of PRTH-101, a novel DDR1 inhibitor aimed at treating advanced or metastatic solid tumours.

The open-label trial will examine the safety, tolerability, and anti-tumour activity of PRTH-101, both as a standalone therapy and in combination with pembrolizumab.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

This study anticipates enrolling up to 270 patients in the US.

It is designed to escalate doses and expand upon determining the optimal dosing regimens for future Phase II clinical programmes.

The trial will also explore DDR1 and related proteins as potential biomarkers for patient responses.

PRTH-101 is an antibody that targets DDR1, a protein involved in tumour growth.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is said to have shown promise in preclinical studies, demonstrating the ability to disrupt tumour defences and enhance the effectiveness of checkpoint inhibitors.

Incendia Therapeutics is at the forefront of developing therapies that alter the tumour microenvironment.

Incendia Therapeutics Development and Operations senior vice-president Irena Webster said: “In our Phase Ia and Ib studies, we were able to select an optimal dose and identify potential biomarkers to carry forward.

“The data from this study will inform the design of the Phase II/III programme, for which planning and global feasibility are currently underway.”

Incendia Therapeutics CMO Dr Joseph Paul Eder said: “Incendia, with its outstanding team of investigators and investigative sites, has determined a recommended Phase II dose of PRTH 101. 

“PRTH 101 has shown consistent safety as a single agent and in combination with pembrolizumab. We will now focus on tumour types that have demonstrated signs of clinical activity and patient benefits.”